Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
CAN CSA C22.2 No. 60601-2-10-14 (2018): Safety Requirements for Nerve and Muscle Stimulators – A Technical Overview
Understanding the Canadian Standard for Medical Electrical Equipment Used in Neuromuscular Stimulation Therapy
Scope and Purpose of CAN CSA C22.2 No. 60601-2-10-14 (2018)
CAN CSA C22.2 No. 60601-2-10-14 (2018) is a Canadian adoption of the international standard IEC 60601-2-10, which specifies particular safety requirements for nerve and muscle stimulators. This standard applies to medical electrical equipment classified as nerve and muscle stimulators, typically used for functional electrical stimulation (FES), transcutaneous electrical nerve stimulation (TENS), or neuromuscular electrical stimulation (NMES) in clinical and home environments.
The standard’s primary objective is to ensure a high level of safety for patients and operators by limiting electrical hazards, thermal risks, and mechanical dangers. It covers all parts that are in direct patient contact, including electrodes, cables, and the stimulation generator itself. CAN CSA C22.2 No. 60601-2-10-14 (2018) also includes requirements for accompanying documents, marking, and testing protocols to verify conformity.
Tip: Although this standard is a Canadian adoption, manufacturers worldwide often reference it for market access in Canada. Understanding its alignment with the base IEC 60601-2-10 (Edition 2.1:2014) is essential for streamlined certification.
The standard applies to devices that deliver pulsed or alternating currents through surface electrodes or needle electrodes (in some specialized cases) for therapeutic purposes. It does not cover implanted stimulators or devices intended for surgical use unless explicitly referenced.
Key Technical Requirements
Electrical Safety and Output Limits
The core of CAN CSA C22.2 No. 60601-2-10-14 (2018) lies in the strict control of output characteristics to prevent tissue damage, burns, or cardiac interference. The standard imposes maximum allowable values for output voltage, current, charge per pulse, and energy per pulse. Table 1 summarizes the critical parameters under normal and single-fault conditions.
| Parameter | Maximum Allowable Value | Test Condition |
|---|---|---|
| Output frequency | ≤ 10 kHz (therapeutic range) | Normal operation |
| Pulse charge (Q) | ≤ 300 μC per pulse | Single fault condition |
| Pulse energy (W) | ≤ 25 mJ per pulse | Single fault condition |
| Output current density | ≤ 30 mA/cm² (electrode area) | Normal operation |
| DC component | ≤ 0 (no net DC) or < 1 mA static | All conditions |
| Patient leakage current | ≤ 50 μA (normal), ≤ 500 μA (single fault) | Per 60601-1 |
Table 1: Key electrical output limits per CAN CSA C22.2 No. 60601-2-10-14 (2018).
Warning: Designers must ensure that the output limits under single-fault conditions (e.g., a component short-circuit) remain within the values given in Table 1. This often requires redundant current-limiting circuits or pulse-width monitoring.
Electrode and Patient Connection Requirements
The standard includes explicit requirements for patient connections to prevent burns at the electrode site. Electrode connectors must be designed to reduce the risk of accidental disconnection or misconnection. For floating (isolated) outputs, the DC blocking capacitor must be rated to withstand test voltages and have a minimum capacitance to avoid saturation.
Additionally, the standard mandates that the user interface clearly indicate the magnitude and duration of stimulation, with warnings if the output exceeds predefined safe limits. Marking of output terminals and polarity (if relevant) must be permanent and legible.
Control and Protection Systems
Stimulators must incorporate an independent protection mechanism that limits the maximum pulse width and frequency. The device should default to a safe mode (e.g., output disabled) following a microprocessor fault. The software used for critical safety functions must comply with IEC 62304, as referenced by the 60601 series.
Implementation and Design Considerations
Manufacturers implementing CAN CSA C22.2 No. 60601-2-10-14 (2018) should adopt a risk management process per ISO 14971. The design of the output stage deserves special attention: many designs use a full-bridge or H-bridge configuration coupled with a step-up transformer to generate high-voltage pulses. The output voltage is often adjustable, but the hardware should inherently prevent exceeding the energy limits.
Best Practice: Use isolated DC-DC converters for the high-voltage supply and optical or magnetic coupling for the control signals. This ensures that even if the primary side fails, the patient connection remains isolated and safe.
If the device supports multiple channels (e.g., eight-channel NMES), each channel must individually meet the output limits. Cross-channel leakage should be monitored, and the overall device leakage current—including from the enclosure and patient leads—must comply with CAN/CSA C22.2 No. 60601-1.
For software‑controlled stimulators, the standard (via 60601-1) requires the software safety classification to be evaluated. If the software controls essential safety functions, it must be developed according to IEC 62304 Class C (highest risk class).
Critical Note: In devices intended for use on the thorax (e.g., chest or neck), additional restrictions on frequency and current apply to prevent respiratory or cardiac interference. Always check the prescription of use as defined by the manufacturer.
Compliance and Certification Requirements
To certify a device to CAN CSA C22.2 No. 60601-2-10-14 (2018), manufacturers must submit a technical file to a recognized certification body (e.g., CSA Group, UL, TÜV SÜD). The assessment includes type tests of the electrical safety parameters listed in Table 1, as well as an evaluation of the risk management file and biocompatibility of electrodes per ISO 10993‑10 (skin irritation) and ISO 10993‑5 (cytotoxicity), if applicable.
Production units must undergo routine testing for dielectric strength and leakage current. The manufacturer’s quality system must be ISO 13485 certified. The standard also emphasizes documentation in both English and French for the Canadian market.
For devices that have been previously certified to IEC 60601-2-10 (2012 or 2014), the transition to CAN CSA C22.2 No. 60601-2-10-14 (2018) may require only a delta assessment if any Canadian-specific deviations exist. However, the standard adopts the 2014 amendment, so any changes from Amendment 1 must be covered.
Tip: Work with a CSA‑accepted lab early in the design phase to avoid costly redesigns. Pre‑compliance testing can identify gaps in output limiting or labeling requirements.
Frequently Asked Questions (FAQs)
Q: What is the exact year of the CAN/CSA version of this standard?
A: The standard number CAN CSA C22.2 No. 60601-2-10-14 (2018) indicates that the edition takes the content up to the 2014 version of IEC 60601-2-10 and was adopted by CSA in 2018. The “14” refers to the base IEC edition year (2014).
A: The standard number CAN CSA C22.2 No. 60601-2-10-14 (2018) indicates that the edition takes the content up to the 2014 version of IEC 60601-2-10 and was adopted by CSA in 2018. The “14” refers to the base IEC edition year (2014).
Q: Does this standard cover TENS devices used for pain relief?
A: Yes. Transcutaneous Electrical Nerve Stimulation (TENS) devices are a subset of nerve stimulators and fall within the scope of this standard, provided they are not implanted and are intended for therapeutic purposes.
A: Yes. Transcutaneous Electrical Nerve Stimulation (TENS) devices are a subset of nerve stimulators and fall within the scope of this standard, provided they are not implanted and are intended for therapeutic purposes.
Q: How does this standard relate to the base safety standard CAN/CSA C22.2 No. 60601-1?
A: It is a particular standard that modifies and supplements the general requirements of 60601-1. For nerve and muscle stimulators, the particular requirements take precedence over the general standard in cases of conflict.
A: It is a particular standard that modifies and supplements the general requirements of 60601-1. For nerve and muscle stimulators, the particular requirements take precedence over the general standard in cases of conflict.
Q: Are there any recent amendments or updates planned after 2018?
A: As of 2026, the IEC has published Edition 3.0 of IEC 60601-2-10 (2021). Canada has not yet adopted this edition; thus, the 2018 version remains the current Canadian standard. Manufacturers should monitor NRCan announcements for future adoptions.
A: As of 2026, the IEC has published Edition 3.0 of IEC 60601-2-10 (2021). Canada has not yet adopted this edition; thus, the 2018 version remains the current Canadian standard. Manufacturers should monitor NRCan announcements for future adoptions.
This article reflects information available as of 2026. Consult the latest published standard from CSA Group for complete and authoritative requirements.